Claims for Patent: 10,179,770

Summary for Patent: 10,179,770

Title:	Quinolines derivatives as novel anticancer agents
Abstract:	The invention provides quinoline derivatives, their manufacture, pharmaceutical compositions containing them, and their use as medicaments. The active compounds of the present invention are useful for the treatment of proliferative neoplastic and non-neoplastic diseases.
Inventor(s):	Courcambeck; Jerome (Marseilles, FR), Halfon; Philippe (Marseilles, FR), Bassissi; Firas (Marseilles, FR), Brun; Sonia (Aix en Provence, FR), Nicolas; Gregory (Marseilles, FR), Beret; Antoine (Marseilles, FR), Petit; Serge (Cusy, FR), Camus; Claire (Marseilles, FR), Nallet; Jean Pierre (Montanay, FR)
Assignee:	GENOSCIENCE PHARMA (Marseilles, FR)
Application Number:	14/777,917
Patent Claims:	1. A compound of formula (I) ##STR00310## wherein: R.sup.l is selected from optionally substituted aryl, optionally substituted heteroaryl, optionally substituted heteroaromatic 5 to 9 membered ring comprising 1, 2 or 3heteroatoms independently selected from O, N, and S; R.sup.2 is selected from Cl, F, I, Br, C.sub.1-C.sub.6 alkyl, C.sub.1-C.sub.6 alkyl substituted with one or more halogens, C.sub.1-C.sub.6 alkoxy, hydroxy, nitro or NR.sup.7R.sup.8, NR.sup.7--(CO)--R.sup.8, NR.sup.7--(CO)--O--R.sup.8, NR.sup.7--(CO)--NR.sup.7R.sup.8, O--(CO)R.sup.7, O--(CO)--O--R.sup.7, O--(CO)--NR.sup.7R.sup.8, (CO)R.sup.7, (CO)--O--R.sup.7, (CO)--NR.sup.7R.sup.8, SO.sub.2--R.sup.7, SO.sub.2NR.sup.7R.sup.8, NR.sup.7--SO.sub.2--R.sup.8, with R.sup.7 and R.sup.8 representing independently hydrogen, C.sub.1-C.sub.6 alkyl, phenyl (optionally substituted with one or more substituent groups selected from Cl, F, I, Br, C1-C6 alkyl, C.sub.1-C.sub.6 alkyl substituted with one or more halogens, C.sub.1-C.sub.6 alkoxy, hydroxy, cyano, nitro or NR.sup.7R.sup.8) or benzyl (optionally substituted with one or more substituent groups selected from Cl, F, I, Br, C.sub.1-C.sub.6 alkyl, C.sub.1-C.sub.6 alkyl substituted with one or more halogens, C.sub.1-C.sub.6 alkoxy, hydroxy, cyano, nitro or NR.sup.7R.sup.8), alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl and heteroaryl; L.sup.l is selected from a bond or from optionally substituted C.sub.1-C.sub.14 alkyl(-R.sup.3), N(--R.sup.3), (CO)--O, (CO)--NR.sup.7, and O; n is 0, 1, 2, 3 or 4; and W is ##STR00311## wherein: L.sub.2 is selected from a bond or from optionally substituted C.sub.1-C.sub.14 alkyl(-R.sup.3), N(--R.sup.3), (CO)--O, (CO)--NR.sup.7, and O; wherein R.sup.3 is selected from H, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted heterocycloalkyl, optionally substituted C.sub.1-C.sub.8 alkyl, optionally substituted C.sub.2-C.sub.8 alkenyl, optionally substituted C.sub.2-C.sub.8 alkynyl, optionally substituted C.sub.3-C.sub.12 cycloalkyl, and optionally substituted C.sub.3-C.sub.12 cycloalkenyl; and wherein R.sup.7 is as defined above; and R.sup.4 and R.sup.5 are independently selected from hydrogen, C.sub.1-C.sub.6 alkyl or phenyl (optionally substituted with one or more substituent groups selected from Cl, F, I, Br, C.sub.1-C.sub.6 alkyl, C.sub.1-C.sub.6 alkyl substituted with one or more halogens, C.sub.1-C.sub.6 alkoxy, hydroxy, cyano, nitro or NR.sup.7R.sup.8) or benzyl (with the phenyl group optionally substituted with one or more substituent groups selected from Cl, F, I, Br, C.sub.1-C.sub.6 alkyl, C.sub.1-C.sub.6 alkyl substituted with one or more halogens, C.sub.1-C.sub.6 alkoxy, hydroxy, cyano, nitro or NR.sup.7R.sup.8) or CH.sub.2--CH.sub.2-Phenyl (with the phenyl group optionally substituted with one or more substituent groups selected from Cl, F, I, Br, C1-C6 alkyl, C.sub.1-C.sub.6 alkyl substituted with one or more halogens, C.sub.1-C.sub.6 alkoxy, hydroxy, cyano, nitro or NR.sup.7R.sup.8), (CO)--R.sup.7, (CO)--OR.sup.7, (CO)--NR.sup.7R.sup.8, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, monocyclic or bicyclic heteroaryl or R.sup.4 and R.sup.5 are linked to form a heterocyclic group, wherein the term "optionally substituted" means optionally substituted with one or more substituents independently selected from Cl, F, I, Br, C.sub.1-C.sub.6 alkyl, C.sub.1-C.sub.6 alkyl substituted with one or more halogens, C.sub.1-C.sub.6 alkoxy, hydroxy, cyano, nitro or NR.sup.7R.sup.8 with R.sup.7 and R.sup.8 representing independently hydrogen, C.sub.1-C.sub.6 alkyl, phenyl (optionally substituted with one or more substituent groups selected from Cl, F, I, Br, C.sub.1-C.sub.6 alkyl, C.sub.1-C.sub.6 alkyl substituted with one or more halogens, C.sub.1-C.sub.6 alkoxy, hydroxy, cyano, nitro or NR.sup.7R.sup.8) or benzyl (optionally substituted with one or more substituent groups selected from Cl, F, I, Br, C.sub.1-C.sub.6 alkyl, C.sub.1-C.sub.6 alkyl substituted with one or more halogens, C.sub.1-C.sub.6 alkoxy, hydroxy, cyano, nitro or NR.sup.7R.sup.8), alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl and heteroaryl; and any pharmaceutically acceptable salt, solvate or prodrug thereof. 2. A compound according to claim 1 of formula (I') ##STR00312## wherein L.sub.1, L.sub.2, R.sup.1, R.sup.2, R.sup.4, R.sup.5 and n are as defined in claim 1; and any pharmaceutically acceptable salt, solvate or prodrug thereof. 3. A compound according to claim 1 selected from the group consisting of: 2-phenyl-4-(4-N,N-diethylamino-piperidin-1-yl)quinoline (I-3); 7-chloro-2-phenyl-4-(4-N,N-diethylamino-piperidin-1yl)quinoline (II-3); 2-phenyl-4-([1,4']-bipiperidin-1'-yl)quinoline (III-3); 2-phenyl-4-(4-N-tert-butylamino-piperidin-1-yl)quinoline (IV-1); 2-phenyl-4-[(4-morpholin-4-yl)piperidin-1-yl]quinoline (V-1); 2-(2-naphtyl)-4-(4-N,N-diethylamino-piperidin-1-yl)quinoline (VI-5); 2-(4-bromo-phenyl)-7-chloro-4-(4-N,N-diethylamino-piperidin-1-yl)quinolin- e (VII-4); 2-(4-bromo-phenyl)-4-(4-N,N-diethylamino-piperidin-1-yl)quinoli- ne (VIII-5); 2-(1,1'-biphenyl)-4-yl-4-(4-N,N-diethylamino-piperidin-1-yl)quinoline (IX-1); 2-(4-chloro-phenyl)-4-(4-N,N-diethylamino-piperidin-1-yl)quinolin- e (X-5); 2-(1,1'-biphenyl)-4-yl-7-chloro-4-(4-N,N-diethylamino-piperidin-1- -yl)quinoline (XI-1); 2-(4-chloro-phenyl)-4-(4-N-tert-butylamino-piperidin-1-yl)quinoline (XII-3); 2-(4-methyl-phenyl)-4-(4-N-tert-butylamino-piperidin-1-yl)quinol- ine (XIII-7); 2-(3,4-dichloro-phenyl)-4-(4-N-tert-butylamino-piperidin-1-yl)quinoline (XIV-7); 2-(4-methoxy-phenyl)-4-(4-N-tert-butylamino-piperidin-1-yl)quino- line (XV-7); 7-Chloro-2-phenyl-4-{1-[4-(N,N-diethylamino)-piperidin-1-yl]-eth-1-yl}1qu- inoline (XVI-3); 7-Chloro-2-phenyl-4-[4-(N,N-diethylamino)-piperidin-1-ylmethyl]quinoline (XVII-5); 2-phenyl-4-{1-[4-(N,N-diethylamino)-piperidin-1-yl]-eth-1-yl}qu- inoline (XIX-2); 2-phenyl-4-[4-(N,N-diethylamino)-piperidin-1-ylmethyl]quinoline (XX-4); 2-phenyl-4-{1-{4-[benzyl(phenethyl)amino]-piperidin-1-yl}-eth-1-yl}quinol- ine (XXI-3); 2-phenyl-4-{1-[(1.4'-bipiperidin)-1'-yl]-eth-1-yl}quinoline (XXII-3); 2-phenyl-4-{1-[4-(tert-butylamino)-piperidin-1-yl]-eth-1-yl}qui- noline (XXIII-1); 2-(2-naphtyl)-4-{1-[4-(N,N-diethylamino)-piperidin-1-yl]-eth-1-yl}quinoli- ne (XXIV-2); 2-phenyl-4-{2-[4-(N,N-diethylamino)-piperidin-1-yl]-propan-2-yl}quinoline trifluoroacetate salt (XXV-6); 7-chloro-2-phenyl-4-[4-(N,N-diethylaminomethyl)-piperidin-1-yl]quinoline (XXVI-3); 2-phenyl-4-[4-(N,N-diethylaminomethyl)-piperidin-1-yl)quinoline (XXVII-1); and 2-phenyl-4-{1-[4-(morpholino)-piperidinyl]-eth-1-yl}quinoline (XLV-1). 4. A compound according to claim 1 selected from the group consisting of: 2-phenyl-4-(4-N,N-diethylamino-piperidin-1-yl)quinoline hydrochloride salt (I-4); 7-chloro-2-phenyl-4-(4-N,N-diethylamino-piperidin-1-yl)quinoline hydrochloride salt (II-4); 2-phenyl-4-([1,4']-bipiperidin-1'-yl)quinoline hydrochloride salt (III-4); 2-phenyl-4-(4-N-tert-butylamino-piperidin-1-yl)quinoline hydrochloride salt (IV-2); 2-phenyl-4-[(4-morpholin-4-yl)piperidin-1yl]quinoline hydrochloride salt (V-2); 2-(2-naphtyl)-4-(4-N,N-diethylamino-piperidin-1-yl)quinoline hydrochloride salt (VI-6); 2-(4-bromo-phenyl)-7-chloro-4-(4-N,N-diethylamino-piperidin-1-yl)quinolin- e hydrochloride salt (VII-5); 2-(4-bromo-phenyl)-4-(4-N,N-diethylamino-piperidin-1-yl)quinoline hydrochloride salt (VIII-6); 2-(1,1'-biphenyl)-4-yl-4-(4-N,N-diethylamino-piperidin-1-yl)quinoline hydrochloride salt (IX-2); 2-(4-chloro-phenyl)-4-(4-N,N-diethylamino-piperidin-1-yl)quinoline hydrochloride salt (X-6); 2-(1,1'-biphenyl)-4-yl-7-chloro-4-(4-N,N-diethylamino-piperidin-1-yl)quin- oline hydrochloride salt (XI-2); 2-(4-chloro-phenyl)-4-(4-N-tert-butylamino-piperidin-1-yl)quinoline hydrochloride salt (XII-4); 2-(4-methyl-phenyl)-4-(4-N-tert-butylamino-piperidin-1-yl)quinoline hydrochloride salt (XIII-8); 2-(3,4-dichloro-phenyl)-4-(4-N-tert-butylamino-piperidin-1-yl)quinoline hydrochloride salt (XIV-8); 2-(4-methoxy-phenyl)-4-(4-N-tert-butylamino-piperidin-1-yl)quinoline hydrochloride salt (XV-8); 7-Chloro-2-phenyl-4-{1-[4-(N,N-diethylamino)-piperidin-1-yl]-eth-1-yl}qui- noline hydrochloride salt (XVI-4); 7-Chloro-2-phenyl-4-[4-(N,N-diethylamino)-piperidin-1-ylmethyl]quinoline hydrochloride salt (XVII-6); 2-phenyl-4-{1-[4-(N,N-diethylamino)-piperidin-1-yl]-eth-1-yl }quinoline hydrochloride salt (XIX-3); 2-phenyl-4-[4-(N,N-diethylamino)-piperidin-1-ylmethyl]quinoline hydrochloride salt (XX-5); 2-phenyl-4-{1-{4-[benzyl(phenethyl)amino]-piperidin-1-yl}-eth-1-yl}quinol- ine hydrochloride salt (XXI-4); 2-phenyl-4-{1-[(1.4'-bipiperidin)-1'-yl]-eth-1-yl}quinoline hydrochloride salt (XXII-4); 2-phenyl-4-{1-[4-(tert-butylamino)-piperidin-1-yl]-eth-1-yl}quinoline hydrochloride salt (XXIII-2); 2-(2-naphtyl)-4-{1-[4-(N,N-diethylamino)-piperidin-1-]-eth-1-yl}quinoline hydrochloride salt (XXIV-3); 2-phenyl-4-{2-[4-(N,N-diethylamino)-piperidin-1-yl]-propan-2-yl}quinoline trifluoroacetate salt (XXV-6) 7-chloro-2-phenyl-4-[4-(N,N-diethylaminomethyl)-piperidin-1-yl]quinoline hydrochloride salt (XXVI-4); 2-phenyl-4-[4-(N,N-diethylaminomethyl)-piperidin-1-yl)quinoline hydrochloride salt (XXVII-2); and 2-phenyl-4-{1-[4-(morpholino)-piperidinyl]-eth-1-yl}quinoline hydrochloride salt (XLV-1). 5. A compound according to claim 1 of formula (Ia) (XIX-2): ##STR00313## or a pharmaceutically acceptable salt, solvate or prodrug thereof. 6. A compound according to claim 1 of formula (Ib) (XLV-1): ##STR00314## or a pharmaceutically acceptable salt, solvate or prodrug thereof. 7. A compound according to claim 1 of formula (Ic) (XII-3): ##STR00315## or a pharmaceutically acceptable salt, solvate or prodrug thereof. 8. A compound according to claim 1 of formula (Id) (XXIV-2): ##STR00316## or a pharmaceutically acceptable salt, solvate or prodrug thereof. 9. A pharmaceutical composition comprising a therapeutically effective amount of a compound according to claim 1, or a pharmaceutically acceptable salt, solvate or prodrug thereof, and a pharmaceutically acceptable adjuvant, diluent or carrier. 10. A pharmaceutical composition according to claim 9 further comprising in combination one or more anti-neoplastic agents. 11. A pharmaceutical composition according to claim 9, wherein the therapeutically effective amount of the compound is formulated or co-formulated in nanoparticles. 12. The pharmaceutical composition according to claim 11, wherein the nanoparticles comprise a polymeric biodegradable composition. 13. The pharmaceutical composition according to claim 12, wherein the polymer is based on Poly (DL-Lactic-co-glycolic acid) having molecular weight from 7 to 240 kDa; or a copolymer of polylactic acid (PLA and polyglycolic acid (PGA) where the molecular ratio is between 95:5 and 50:50. 14. The pharmaceutical composition according to claim 11, wherein the nanoparticles comprise a lisosomal biodegradable composition. 15. The pharmaceutical composition according to claim 11, wherein the nanoparticles comprise a biocompatible polymer or copolymer. 16. The pharmaceutical composition according to claim 11, wherein the nanoparticles are associated covalently or non-covalently with a polyethylene glycol (PEG). 17. The pharmaceutical composition according to claim 11, wherein the nanoparticles have an average size of from about 80 to about 600 nm. 18. The pharmaceutical composition according to claim 11, wherein the compound is associated with at least one therapeutically active anti-cancer agent. 19. The pharmaceutical composition according to claim 11, which is suitable for oral-, parenteral-, ocular-, transdermal-, nasal-administration, or for inhalation. 20. A pharmaceutical composition according to claim 11, wherein the nanoparticles comprise an item selected from PLGA nanoparticules, PLGA-PEG nanoparticles (block type AB, BA, ABA or BAB, where A =PLGA and B =PEG) and targeted nanoparticules. 21. A pharmaceutical composition according to claim 20, wherein the nanoparticle is a targeted nanoparticle containing a signaling motif. 22. A pharmaceutical composition comprising a combination of a therapeutically effective amount of a compound according to claim 1, and a therapeutically effective amount of one or more anti-neoplastic agents, wherein the components constituting said combination are for simultaneous, separate or sequential use in cancer therapy. 23. The pharmaceutical composition of claim 10, wherein the anti-neoplastic agent is selected from the group consisting of everolimus, chloroquine, hydroxychloroquine, trabectedin, abraxane, TLK 286, AV-299, DN-101, pazopanib, GSK690693, RTA 744, ON 0910.Na, AZD 6244 (ARRY-142886), AMN-107, TKI-258, GSK461364, AZD 1152, enzastaurin, vandetanib, ARQ-197, MK-0457, MLN8054, PHA-739358, R-763, AT-9263, pemetrexed, erlotinib, dasatanib, nilotinib, decatanib, panitumumab, amrubicin, oregovomab, Lep-etu, nolatrexed, azd2171, batabulin, ofatumumab, zanolimumab, edotecarin, tetrandrine, rubitecan, tesmilifene, oblimersen, ticilimumab, ipilimumab, gossypol, Bio 111, 131-I-TM-601, ALT-110, BIO 140, CC 8490, cilengitide, gimatecan, IL13-PE38QQR, TNO 1001, IPdR1 KRX-0402, lucanthone, LY 317615, neuradiab, vitespan, Rta 744, Sdx 102, talampanel, atrasentan, Xr 311, romidepsin, ADS-100380, sunitinib, 5-fluorouracil, vorinostat, etoposide, gemcitabine, doxorubicin, irinotecan, liposomal doxorubicin, 5'-deoxy-5-fluorouridine, vincristine, temozolomide, ZK-304709,seliciclib, PD0325901, AZD-6244, capecitabine, L-Glutamic acid, N-[4-[2-(2-amino-4,7-dihydro-4-oxo-1H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]- benzoyl]-disodium salt heptahydrate, camptothecin, PEG-labeled irinotecan, tamoxifen, toremifene citrate, anastrazole, exemestane, letrozole, DES(diethylstilbestrol), estradiol, estrogen, conjugated estrogen, bevacizumab, IMC-1C11, CHIR-258, 3-[5-(methylsulfonylpiperadinemethyl)-indolyl]-quinolone, vatalanib, AG-013736, AVE-0005, the acetate salt of [D-Ser(But).sub.6, Azgly.sub.10](pyro-Glu-His-Trp-Ser-Tyr-D-Ser(But)-Leu-Arg-Pro-Azgly-NH.su- b.2 acetate [C.sub.59H.sub.84N.sub.18O.sub.14--(C.sub.2H.sub.4O.sub.2)x where x =1 to 2.4], goserelin acetate, leuprolide acetate, triptorelin pamoate, medroxyprogesterone acetate, hydroxyprogesterone caproate, megestrol acetate, raloxifene, bicalutamide, flutamide, nilutamide, megestrol acetate, CP-724714; TAK-165, HKI-272, erlotinib, lapatanib, canertinib, ABX-EGF antibody, erbitux, EKB-569, PM-166, GW-572016, lonafarnib, BMS-214662, tipifarnib; amifostine, NVP-LAQ824, suberoyl analide hydroxamic acid, valproic acid, trichostatin A, FK-228, SU11248, sorafenib, KRN951, aminoglutethimide, amsacrine, anagrelide, L-asparaginase, Bacillus Calmette-Guerin (BCG) vaccine, bleomycin, buserelin, busulfan, carboplatin, carmustine, chlorambucil, cisplatin, cladribine, clodronate, cyproterone, cytarabine, dacarbazine, dactinomycin, daunorubicin, diethylstilbestrol, epirubicin, fludarabine, fludrocortisone, fluoxymesterone, flutamide, gemcitabine, gleevac, hydroxyurea, idarubicin, ifosfamide, imatinib, leuprolide, levamisole, lomustine, mechlorethamine, melphalan, 6-mercaptopurine, mesna, methotrexate, mitomycin, mitotane, mitoxantrone, nilutamide, octreotide, oxaliplatin, pamidronate, pentostatin, plicamycin, porfimer, procarbazine, raltitrexed, rituximab, streptozocin, teniposide, testosterone, thalidomide, thioguanine, thiotepa, tretinoin, vindesine, 13-cis-retinoic acid, phenylalanine mustard, uracil mustard, estramustine, altretamine, floxuridine, 5-deoxyuridine, cytosine arabinoside, 6-mecaptopurine, deoxycoformycin, calcitriol, valrubicin, mithramycin, vinblastine, vinorelbine, topotecan, razoxin, marimastat, COL-3, neovastat, BMS-275291, squalamine, endostatin, SU5416, SU6668, EMD121974, interleukin-12, 1M862, angiostatin, vitaxin, droloxifene, idoxyfene, spironolactone, finasteride, cimitidine, trastuzumab, denileukin diftitox, gefitinib, bortezimib, paclitaxel, irinotecan, topotecan, doxorubicin, docetaxel, vinorelbine, bevacizumab (monoclonal antibody) and erbitux, cremophor-free paclitaxel, epithilone B, BMS-247550, BMS-310705, droloxifene, 4-hydroxytamoxifen, pipendoxifene, ERA-923, arzoxifene, fulvestrant, acolbifene, lasofoxifene, idoxifene, TSE-424, HMR-3339, ZK186619, PTK787/ZK 222584, VX-745, PD 184352, rapamycin, 40-O-(2-hydroxyethyl)-rapamycin, temsirolimus, AP-23573, RAD001, ABT-578, BC-210, LY294002, LY292223, LY292696, LY293684, LY293646, wortmannin, ZM336372, L-779,450, PEG-filgrastim, darbepoetin, erythropoietin, granulocyte colony-stimulating factor, zolendronate, prednisone, cetuximab, granulocyte macrophage colony-stimulating factor, histrelin, pegylated interferon alfa-2a, interferon alfa-2a, pegylated interferon alfa-2b, interferon alfa-2b, azacitidine, PEG-L-asparaginase, lenalidomide, gemtuzumab, hydrocortisone, interleukin-11, dexrazoxane, alemtuzumab, all-transretinoic acid, ketoconazole, interleukin-2, megestrol, nitrogen mustard, methylprednisolone, ibritumomab tiuxetan, androgens, decitabine, hexamethylmelamine, bexarotene, tositumomab, arsenic trioxide, cortisone, editronate, mitotane, cyclosporine, liposomal daunorubicin, Edwina-asparaginase, strontium 89, casopitant, netupitant, an NK-1 receptor antagonists, palonosetron, aprepitant, diphenhydramine, hydroxyzine, metoclopramide, lorazepam, alprazolam, haloperidol, droperidol, dronabinol, dexamethasone, methylprednisolone, prochlorperazine, granisetron, ondansetron, dolasetron, tropisetron, sspegfilgrastim, epoetin alfa and darbepoetin alfa, ipilumumab, vemurafenib, FLT-3 inhibitor, a VEGFR inhibitor, an EGFR TK inhibitor, an aurora kinase inhibitor, a PIK-1 modulator, a mTOR inhibitor, a Bcl-2 inhibitor, an HDAC inhibitor, a c-MET inhibitor, a PARP inhibitor, a Cdk inhibitor, an EGFR TK inhibitor, an IGFR-TK inhibitor, an anti-HGF antibody, a PI3 kinase inhibitors, an AKT inhibitor, a JAK/STAT inhibitor, a checkpoint-1 or 2 inhibitor, a focal adhesion kinase inhibitor, a Map kinase (mek) inhibitor, a VEGF trap antibody, and mixtures thereof. 24. The pharmaceutical composition according to claim 9, which is suitable for slow- or sustained-release. 25. A method for the treatment and/or prevention of a proliferative and/or neoplastic disease, comprising the step of administering a therapeutically active amount of a compound according to claim 1, or a pharmaceutical composition comprising a therapeutically effective amount of the compound or a pharmaceutically acceptable salt, solvate or prodrug thereof, and a pharmaceutically acceptable adjuvant, diluent or carrier, to a human being or animal in need thereof. 26. A method according to claim 25, wherein the proliferative and/or neoplastic disease is selected from the group consisting of: carcinoma; a leukemia; a malignant lymphoma; a malignant melanoma; myeloproliferative diseases; a sarcoma; a tumor of the central nervous system; a germ-line tumor; testicular cancer; thyroid cancer; astrocytoma; colon cancer, melanoma, and a mixed type of neoplasia. 27. A method according to claim 26, wherein the carcinoma is a cancer of the esophagus, head, kidney, liver, lung, nasopharyngeal, neck, ovary, pancreas, prostate, stomach, breast or colon. 28. A method according to claim 26, wherein the leukemia is acute myelogenous leukemia, acute lymphocytic leukemia, acute promyelocytic leukemia (APL), acute T-cell lymphoblastic leukemia, adult T-cell leukemia, basophilic leukemia, eosinophilic leukemia, granulocytic leukemia, hairy cell leukemia, leukopenic leukemia, lymphatic leukemia, lymphoblastic leukemia, lymphocytic leukemia, megakaryocytic leukemia, micromyeloblastic leukemia, monocytic leukemia, neutrophilic leukemia and stem cell leukemia. 29. A method for inhibiting the growth or differentiation of a Cancer Stem Cell (CSC), a tumor initiating cell, a mesenchymal-like cell associated with cancer, a mesenchymal cancerous cell, or a mesenchymal cell comprising the step of administering a therapeutically active amount of a compound according to claim 1, or a pharmaceutical composition comprising a therapeutically effective amount of the compound or a pharmaceutically acceptable salt, solvate or prodrug thereof, and a pharmaceutically acceptable adjuvant, diluent or carrier, to a human being or an animal in need thereof.

Details for Patent 10,179,770

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Recordati Rare Diseases, Inc.	ELSPAR	asparaginase	For Injection	101063	01/10/1978		2039-02-26
Merck Teknika Llc	TICE BCG	bcg live	For Injection	102821	06/21/1989		2039-02-26
Merck Teknika Llc	N/A	bcg vaccine	For Injection	103050	06/21/1989		2039-02-26
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2039-02-26
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2039-02-26